

# Elafin Myocardial Protection from Ischaemia RepErfusion injury

<b>Submission date</b> 26/01/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 14/03/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 02/06/2017	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Heart muscle cells are susceptible to injury and death following interruption of blood flow. A mild form of injury occurs during coronary artery bypass surgery (a surgical procedure used to treat coronary heart disease). Certain white blood cells contribute to this heart injury by releasing enzymes that break down the tissues. Elafin is a naturally occurring protein that can potentially reduce heart injury by blocking these harmful enzymes. We believe that administering elafin to patients undergoing coronary artery bypass surgery will reduce heart injury and potentially improve patient outcome. This study sets out to determine whether elafin can indeed benefit patients in this setting.

### Who can participate?

Patients who are 18 years or older undergoing coronary artery bypass graft surgery requiring two or more grafts will be approached to enter the study at Edinburgh Royal Infirmary.

### What does the study involve?

If you consent to participating in the trial you will receive the following additional tests over and above your routine clinical care.

#### 1. Cardiovascular magnetic resonance imaging (MRI) heart scan

You will attend for either two or three cardiovascular MRI heart scans on separate days. The first will be conducted within a period of 6 weeks before your operation. The second and third scans will be conducted on consecutive days ideally between day 5 and day 9 after the operation. In order for us to look in more detail at the heart we will administer an agent called gadolinium through a vein in your arm before the scan. Gadolinium is in routine clinical use.

If you are due to get all three MRI scans, we will administer microscopic iron particles, known as ferumoxytol (the trade name is Feraheme) after the second MRI scan. Ferumoxytol is approved for use in the treatment of anaemia and is safely used at the same dose that we propose to give. It has also been used in MRI scanning at this dose but has not been used after bypass surgery in this way. It will be given through a vein in your arm. Your blood pressure will be recorded before the infusion and 30 minutes after the infusion. The infusion itself will take less than a minute. Twenty-four hours after the ferumoxytol infusion, you will undergo the final MRI scan of the heart

#### 2. Blood tests and drug administration

On the day of surgery you will be allocated at random to receive either the study drug (Elafin) or a dummy drug (saline) during the operation. The research team, surgical team and you will not know which of these treatments is given.

During and after surgery blood tests will be taken from a plastic tube (cannula) that is inserted as part of your routine care during the operation. These blood tests will be used to measure heart muscle injury and inflammation. If you participate in the study a small amount of extra blood will be taken for analysis (around 40 ml in total). This will be frozen and stored until we analyse for the different markers of muscle injury and inflammation.

### 3. Coronary bypass surgery and cardiopulmonary bypass

Patients will have their operation conducted on a cardiopulmonary bypass circuit. This approach is used in over half of coronary bypass operations in Edinburgh. Off-pump surgery is an alternative approach which will not be used in this study. Both techniques are very successful and there is no difference in safety or clinical outcome.

### What are the possible benefits and risks of participating?

It is not thought that there are many disadvantages. Previous studies with Elafin in humans including healthy volunteers and surgical patients have suggested that it is a drug with no specific toxicity or side effects. With any drug there is a possible low risk of allergic reaction and you will be monitored for this as part of the trial. There is a similar low risk of reactions to the contrast agents given for the MRI study. The injection of ferumoxytol should not be painful and has not been associated with any significant side effects. However, we will monitor carefully for these at the time of the administration of ferumoxytol and afterwards and would treat you as necessary. People who have a past history of allergies to iron-containing compounds or 'dextran' (a component of ferumoxytol) would be excluded from the final MRI scan. The iron particles will be degraded by your body and removed by your liver. Because we will be giving extra iron, people with a history of conditions associated with abnormally high quantities of iron in the body will be excluded from the final MRI scan. Because MRI scanners use strong magnets, we will complete a detailed safety questionnaire before you enrol in the study to check that there is no reason why it would be unsafe for you to have a scan. People with metal joint replacements, pacemakers or a history of eye injury involving metal (such as from shrapnel or welding) will not be able to take part. Patients who have had brain surgery with the implantation of metalwork will also have to be excluded. MRI scanners do not use x-rays and therefore are not associated with the risks of radiation associated with other imaging methods including CT scans. Other than the risk associated with MRI in people with metal implants, there are no known risks from MRI scanning. The MRI scanner is noisy, so you will wear special headphones to reduce the noise.

### Where is the study run from?

Edinburgh Heart Centre (Edinburgh, UK).

### When is the study starting and how long is it expected to run for?

The study started in March 2011 and will finish in March 2014. Recruitment ends in September 2013.

### Who is funding the study?

The value and importance of this study has been recognised by the Medical Research Council, who have agreed to fund it after rigorous peer-review.

### Who is the main contact?

Dr Peter Henriksen

phenrik1@staffmail.ed.ac.uk

# Contact information

## Type(s)

Scientific

## Contact name

Dr Peter Henriksen

## Contact details

Department of Cardiology  
Western General Hospital  
Crewe Road  
Edinburgh  
United Kingdom  
EH4 2XU  
+44 (0)131 5373834  
phenrik1@staffmail.ed.ac.uk

# Additional identifiers

## EudraCT/CTIS number

2010-019527-58

## IRAS number

## ClinicalTrials.gov number

## Secondary identifying numbers

010506

# Study information

## Scientific Title

A randomised trial to investigate the effect of Elafin on myocardial injury and inflammation in coronary artery bypass surgery

## Acronym

The EMPIRE study

## Study objectives

Elafin has cardioprotective effects in myocardial injury.

On 23/07/2013, the target number of participants was changed from 80 to 118 (80 full protocol + 38 extension recruits with no MRI scanning protocol). Other changes are indicated in the corresponding fields.

## Ethics approval required

Old ethics approval format

**Ethics approval(s)**

Scotland A Research Ethics Committee, 18/02/2011, ref:11/MRE00/5

**Study design**

Single-centre randomised double-blinded placebo-controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Post-ischaemic inflammatory myocardial injury

**Interventions**

Current interventions as of 23/07/2013:

80 patients will receive an initial magnetic resonance imaging (MRI) scan. They will be randomised to either placebo or Elafin (200 mg) and patients will receive an infusion of this during cardiac bypass surgery. During and after surgery, blood samples will be taken up to 48 hours post-surgery. A second MRI scan will be performed after  $7 \pm 2$  days. After this scan, patients will receive an infusion of Feraheme®. A third MRI scan will be performed 24 hours after the second scan, which will be the end of the trial for patients. Patients in the extension group will be randomised to either placebo or Elafin (200 mg) and will receive an infusion of this during cardiac bypass surgery. During and after surgery, blood samples will be taken up to 48 hours post-surgery, at which point participation in the study will be complete.

Previous interventions:

Patients will receive an initial magnetic resonance imaging (MRI) scan. They will be randomised to either placebo or Elafin (200 mg) and patients will receive an infusion of this during cardiac bypass surgery. During and after surgery blood samples will be taken up to 48 hours post-surgery. A second MRI scan will be performed after  $7 \pm 2$  days. After this scan patients will receive an infusion of Feraheme®. A third MRI scan will be performed 24 hours after the second scan, which will be the end of the trial for patients.

**Intervention Type**

Drug

**Phase**

Phase II

**Drug/device/biological/vaccine name(s)**

Elafin, Feraheme®

**Primary outcome measure**

Area under the curve for plasma troponin I concentration profile over the first 48 hours

**Secondary outcome measures**

1. The effect of Elafin on myocardial injury and inflammation will be further quantified by comparing infarct volume and macrophage infiltration before and after surgery
2. Infarct volume and macrophage infiltration will be quantified using MRI together with late gadolinium enhancement and accumulation of ultra-small superparamagnetic particles of iron oxide (USPIO) respectively. USPIO contrast acts as a cellular marker through the detection of macrophage-mediated inflammation within tissues (added 23/07/2013: not applicable to extension participants)
3. Elafin's effect on inflammatory activation will be assessed by comparing peak and area under the curve of plasma CRP and cytokine (IL-6, TNF-a and IL-8) concentrations
4. Neutrophil activation will be assessed by measuring the white cell and neutrophil differential counts and measuring peak and area under the curve of plasma myeloperoxidase and elastase concentrations
5. Post-operative intensive therapy unit (ITU) stay will be recorded from the end of the operation (as documented on the anaesthetic chart) until the ITU team consider the patient fit for 'step down' either to cardiothoracic high dependency unit (HDU) or general surgical ward. It will be measured in hours.

**Overall study start date**

01/03/2011

**Completion date**

01/03/2014

**Eligibility****Key inclusion criteria**

Patients (males and females, 18 years or older; no upper age limit) who are referred for coronary artery bypass graft surgery requiring two or more grafts will be approached for consent to enter the study during visits to the cardiothoracic surgery outpatient clinic.

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

118 (80 full protocol + 38 extension recruits with no MRI scanning protocol)

**Key exclusion criteria**

1. Recent myocardial infarction (a recorded troponin elevation within 1 month of surgery)
2. Emergency surgery
3. Concomitant valve or aortic surgery
4. Re-intervention or re-do surgery
5. Chronic renal failure (estimated glomerular filtration rate less than 40 ml/min)
6. Severe respiratory disease (maintenance corticosteroid therapy or forced expiratory volume in one second [FEV1] less than 50% predicted)
7. Severe left ventricular dysfunction (ejection fraction less than 30%)
8. Contraindication to magnetic resonance imaging (MRI) scanning or a history of chronic inflammatory illness, such as inflammatory joint disease, connective tissue disorder (added 23/07/2013: not applicable to extension participants)
9. Patients unable to give informed consent

**Date of first enrolment**

01/03/2011

**Date of final enrolment**

01/09/2013

**Locations****Countries of recruitment**

Scotland

United Kingdom

**Study participating centre**

**Western General Hospital**

Edinburgh

United Kingdom

EH4 2XU

**Sponsor information****Organisation**

NHS Lothian and the University of Edinburgh (UK)

**Sponsor details**

The Queen's Medical Research Institute

47 Little France Crescent

Edinburgh

Scotland

United Kingdom

EH16 4TJ  
+44 (0)131 242 9262  
marise.bucukoglu@ed.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.accord.ed.ac.uk>

**ROR**

<https://ror.org/03q82t418>

## **Funder(s)**

**Funder type**

Research council

**Funder Name**

Medical Research Council (MRC) (UK) (ref: 96182)

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

**Funder Name**

Chest Heart Stroke Scotland (UK) (ref: r11/A135)

**Alternative Name(s)**

CHSS

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Associations and societies (private and public)

**Location**

United Kingdom

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2015		Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No